152 related articles for article (PubMed ID: 8976822)
21. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.
Vadhan-Raj S; Kudelka AP; Garrison L; Gano J; Edwards CL; Freedman RS; Kavanagh JJ
J Clin Oncol; 1994 Apr; 12(4):707-14. PubMed ID: 8151314
[TBL] [Abstract][Full Text] [Related]
22. Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.
Trump DL; Grem JL; Tutsch KD; Willson JK; Simon KJ; Alberti D; Storer B; Tormey DC
J Clin Oncol; 1987 Aug; 5(8):1281-9. PubMed ID: 3040920
[TBL] [Abstract][Full Text] [Related]
23. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.
Shea TC; Mason JR; Storniolo AM; Newton B; Breslin M; Mullen M; Ward DM; Miller L; Christian M; Taetle R
J Clin Oncol; 1992 Mar; 10(3):464-73. PubMed ID: 1740685
[TBL] [Abstract][Full Text] [Related]
24. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Selvaggi G; Belani CP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
[TBL] [Abstract][Full Text] [Related]
25. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
26. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
Santini V
Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
[TBL] [Abstract][Full Text] [Related]
27. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Capizzi RL
Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
[TBL] [Abstract][Full Text] [Related]
28. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
29. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
30. Radiochemotherapy with amifostine cytoprotection for head and neck cancer.
Büntzel J; Schuth J; Küttner K; Glatzel M
Support Care Cancer; 1998 Mar; 6(2):155-60. PubMed ID: 9540175
[TBL] [Abstract][Full Text] [Related]
31. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
32. [Ethyol (amifostine): application trial in pediatric oncology].
Korzon M; Popadiuk S; Plata-Nazar K; Gołebiewski J; Szarszewski A; Czauderna P; Stoba C
Wiad Lek; 1998; 51 Suppl 4():215-9. PubMed ID: 10731971
[TBL] [Abstract][Full Text] [Related]
33. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
Peters GJ; van der Vijgh WJ
Eur J Cancer; 1995; 31A Suppl 1():S1-7. PubMed ID: 7577093
[TBL] [Abstract][Full Text] [Related]
34. Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.
Fiorentini G; Giovanis P; Leoni M; De Giorgi U; Cariello A; Dazzi C; Caldeo A
Hepatogastroenterology; 2001; 48(38):313-6. PubMed ID: 11379297
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.
Hilpert F; Stähle A; Tomé O; Burges A; Rossner D; Späthe K; Heilmann V; Richter B; du Bois A;
Support Care Cancer; 2005 Oct; 13(10):797-805. PubMed ID: 16025262
[TBL] [Abstract][Full Text] [Related]
37. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.
Taguchi J; Saijo N; Miura K; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sakurai M; Minato K; Fujiwara Y
Jpn J Cancer Res; 1987 Sep; 78(9):977-82. PubMed ID: 3117753
[TBL] [Abstract][Full Text] [Related]
38. Amifostine: potential for clinically useful cytoprotection.
Budd GT; Lorenzi V; Ganapathi R; Adelstein D; Pelley R; Olencki T; McLain D; Bukowski RM
Support Care Cancer; 1994 Nov; 2(6):380-4. PubMed ID: 7858931
[TBL] [Abstract][Full Text] [Related]
39. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Br J Cancer; 1997; 75(10):1439-46. PubMed ID: 9166935
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
Johnson PW; Muers MF; Peake MD; Poulter KM; Gurney EM; Napp VV; Hepburn PM; Brown JM
Br J Cancer; 2001 Jan; 84(1):19-24. PubMed ID: 11139307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
